Online inquiry

IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13296MR)

This product GTTS-WQ13296MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13296MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14945MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ14991MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ11265MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ960MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ12641MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ1884MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ6497MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ12280MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW